When will the patents on LEUKERAN expire, and when will LEUKERAN go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Waylis Therap	LEUKERAN	chlorambucil	TABLET;ORAL	010669-002	Approved Prior to Jan 1, 1982		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 18, 2026

This analysis assesses the investment potential of LEUKERAN (chlorambucil), a chemotherapy agent. The current market position, patent landscape, clinical development, and competitive environment are evaluated to inform R&D and investment decisions.

What is LEUKERAN (Chlorambucil)?

LEUKERAN, the brand name for chlorambucil, is an alkylating agent used in the treatment of various cancers. It functions by damaging the DNA of cancer cells, inhibiting their proliferation. Originally developed by Burroughs Wellcome, it has a long history of clinical use, primarily in the treatment of chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma, non-Hodgkin's lymphoma, and certain autoimmune diseases like nephrotic syndrome.

Chlorambucil is administered orally, offering a less invasive route compared to intravenous chemotherapy. Its mechanism of action involves forming covalent bonds with DNA, leading to cross-linking of DNA strands and disruption of DNA replication and transcription. This ultimately induces apoptosis in rapidly dividing cells, including cancerous ones.

What is the Current Market Position of LEUKERAN?

LEUKERAN (chlorambucil) occupies a mature segment of the oncology market. Its established efficacy and oral administration have secured its place in treatment protocols, particularly for specific hematological malignancies and in certain therapeutic contexts where newer agents may not be preferred or available.

The global market for chemotherapy drugs is substantial and projected to grow, driven by increasing cancer incidence and advancements in treatment modalities. However, within this broad market, chlorambucil faces competition from a growing number of targeted therapies and immunotherapies that often offer improved efficacy and reduced side effects.

The primary indications for LEUKERAN are:

Chronic Lymphocytic Leukemia (CLL): Historically a cornerstone therapy, often used in combination with corticosteroids.
Hodgkin's Lymphoma: Employed in certain treatment regimens, particularly for relapsed or refractory disease.
Non-Hodgkin's Lymphoma: Similar to Hodgkin's lymphoma, used in specific subtypes and settings.
Other Cancers: Including Waldenström's macroglobulinemia and malignant effusions.
Autoimmune Diseases: Notably nephrotic syndrome in children, where it is used to induce remission in steroid-dependent or frequently relapsing cases.

The market share of chlorambucil is likely declining in developed markets due to the advent of newer, more targeted, and often more effective treatments. However, its lower cost and oral availability may ensure continued use in certain geographic regions and patient populations where access to advanced therapies is limited.

What is the Patent Landscape for LEUKERAN?

LEUKERAN (chlorambucil) is an old drug, with its initial patents having long expired. The original composition of matter patents would have lapsed decades ago. This means that there is no active patent protection covering the molecule itself that would prevent generic manufacturers from producing and selling chlorambucil.

The intellectual property landscape for chlorambucil is characterized by:

Expired Composition of Matter Patents: The foundational patents covering the chemical entity of chlorambucil are no longer in force.
Potential for Process Patents: While unlikely to be a significant barrier for established generic manufacturers, there could be patents on specific manufacturing processes or polymorphs that might offer limited protection.
Exclusivity for Formulations: Newer formulations, such as extended-release versions or combinations with other drugs, might be eligible for patent protection, but no such significant innovations for chlorambucil have emerged to create new market exclusivity.
Data Exclusivity: For newly approved indications or specific patient populations, there might be periods of data exclusivity granted by regulatory bodies, but this is generally tied to new clinical trial data submission and is not a long-term patent.

The lack of patent protection for the active pharmaceutical ingredient (API) has led to widespread generic availability of chlorambucil. This drives down prices and intensifies competition, making it difficult for a single entity to command a significant market share solely based on the molecule.

What is the Clinical Development Status of LEUKERAN?

The clinical development of LEUKERAN (chlorambucil) is largely completed, as it is a well-established drug with decades of clinical use and documented efficacy. There are no major ongoing Phase III trials for new indications or significant novel formulations of chlorambucil that are likely to generate substantial new intellectual property or market expansion.

Key aspects of its clinical development status include:

Established Efficacy and Safety Profile: Extensive clinical data exists across multiple indications, providing a well-understood risk-benefit profile.
Limited Pipeline Activity: Unlike novel therapeutics with active R&D pipelines, chlorambucil's development primarily focuses on its existing approved uses. There are no significant ongoing clinical trials for new cancer targets or major disease areas that suggest a resurgence in clinical development for the molecule itself.
Use in Combination Therapies: Chlorambucil continues to be studied and used in combination regimens, particularly in hematological malignancies. However, the novelty in these studies often lies with the other agents being investigated rather than chlorambucil itself.
Off-Label Uses: Like many older drugs, chlorambucil may have some off-label uses in clinical practice, but these are not typically drivers of major new development or market expansion.
Repurposing Efforts: While not a major trend for chlorambucil, some older drugs are occasionally explored for repurposing. However, there is no significant evidence of widespread, well-funded repurposing efforts for chlorambucil in areas outside of its current oncology and autoimmune indications.

The clinical development of chlorambucil is therefore characterized by its maturity rather than innovation. Investment in extensive new clinical trials for chlorambucil as a standalone agent for new indications is unlikely due to its established nature and the presence of more modern therapeutic options.

What is the Competitive Landscape for LEUKERAN?

The competitive landscape for LEUKERAN (chlorambucil) is intense and multi-faceted, primarily driven by generic competition and the emergence of newer, more targeted therapies.

Direct Competitors (Generic Chlorambucil): The most significant competition comes from generic manufacturers producing chlorambucil. Companies like Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, and Accord Healthcare are among those that offer generic versions, leading to price erosion and limited pricing power for any single brand.

Indirect Competitors (Alternative Therapies): In its primary indications, LEUKERAN faces substantial competition from newer drug classes:

Chronic Lymphocytic Leukemia (CLL):
- BTK Inhibitors: Ibrutinib (Imbruvica), acalabrutinib (Calquence), zanubrutinib (Brukinsa). These targeted therapies have largely become first-line or preferred second-line options due to superior efficacy and often better tolerability compared to traditional chemotherapy.
- BCL-2 Inhibitors: Venetoclax (Venclexta), often used in combination with monoclonal antibodies (e.g., rituximab, obinutuzumab) or chemotherapy. Venetoclax-based regimens have shown high rates of deep remission.
- Monoclonal Antibodies: Rituximab (Rituxan), obinutuzumab (Gazyva). These are frequently used in combination regimens.
- Chemoimmunotherapy: FCR (fludarabine, cyclophosphamide, rituximab) remains a benchmark for younger, fit patients, but newer agents are increasingly displacing it.
Lymphomas (Hodgkin's and Non-Hodgkin's):
- Targeted Therapies: Various targeted agents are used depending on lymphoma subtype, including proteasome inhibitors and antibody-drug conjugates.
- Immunotherapies: Checkpoint inhibitors are gaining traction in Hodgkin's lymphoma.
- Novel Chemotherapy Regimens: While chlorambucil might be part of older regimens (e.g., CHOP), newer combinations or sequential therapies are often employed.
Autoimmune Diseases (e.g., Nephrotic Syndrome):
- Corticosteroids: Still a primary treatment, but chlorambucil is used when steroids are insufficient.
- Other Immunosuppressants: Cyclosporine, tacrolimus, and mycophenolate mofetil are also utilized.

Key Competitive Dynamics:

Efficacy and Safety: Newer agents often demonstrate superior efficacy in achieving remission, prolonging survival, and offer more favorable safety profiles, reducing the severe side effects associated with traditional chemotherapy.
Patient Preference: Oral administration of chlorambucil is an advantage, but the convenience and efficacy of newer oral targeted therapies can outweigh this.
Cost: Generic chlorambucil is significantly cheaper than many novel targeted therapies and biologics. This makes it a vital option in resource-limited settings.
Treatment Guidelines: Evolving clinical practice guidelines for various cancers often prioritize newer agents, impacting prescription patterns.

What are the Financial and Market Projections for Chlorambucil?

Given its status as an old, off-patent drug with significant generic competition and the advent of superior novel therapies, LEUKERAN (chlorambucil) is unlikely to experience substantial market growth. Its financial trajectory is characterized by gradual decline in developed markets, offset by continued use in specific regions and indications.

Key Financial and Market Factors:

Market Size: The specific market size for branded LEUKERAN is difficult to ascertain due to the prevalence of generic chlorambucil. The overall chlorambucil market (including generics) is likely to be in the low hundreds of millions of USD globally, with a downward trend.
Revenue Trends: Brand LEUKERAN revenue has been in steady decline for years, as generic penetration is nearly 100% in many markets. Generic chlorambucil revenue will also likely see gradual declines as newer therapies become more accessible and preferred, even in developing markets.
Pricing Pressure: Intense competition among generic manufacturers leads to significant price erosion. The average selling price (ASP) for chlorambucil has decreased substantially over its lifecycle.
Growth Drivers: Minimal to none for the molecule itself. Potential for very niche growth might arise from specific, low-cost combination therapies or continued use in emerging markets where advanced therapies are cost-prohibitive.
Future Projections: The global market for chlorambucil is projected to contract by a low single-digit percentage annually over the next five to seven years. Continued obsolescence in first-line treatment for major indications will drive this decline.
Manufacturing Costs: Production costs for chlorambucil are relatively low, enabling profitability even at low ASPs for efficient generic manufacturers.
Generic Market Dominance: The market is dominated by generic products. Any investment would need to consider the competitive landscape of generic manufacturers rather than focusing on a branded product with limited lifespan.

Key Takeaways

LEUKERAN (chlorambucil) is a mature chemotherapy agent with expired patents. Its primary indications are hematological malignancies and certain autoimmune conditions. The market is dominated by generic competition, leading to significant price erosion. Newer targeted therapies and immunotherapies offer superior efficacy and safety profiles, increasingly displacing chlorambucil in developed markets. Clinical development for chlorambucil is largely complete, with no significant pipeline activity. Financial projections indicate a declining market, with its continued relevance primarily in resource-limited settings and as a legacy treatment option.

Frequently Asked Questions

Are there any remaining patents that protect LEUKERAN (chlorambucil)? No, all composition of matter patents for chlorambucil have long expired. Intellectual property protection is limited to potential, very specific manufacturing processes or novel formulations, which are not significant barriers to generic production.
What is the primary competition for LEUKERAN in its main indications? In Chronic Lymphocytic Leukemia (CLL), the primary competitors are BTK inhibitors (ibrutinib, acalabrutinib) and BCL-2 inhibitors (venetoclax), often used in combination with monoclonal antibodies. For lymphomas, a range of targeted therapies, immunotherapies, and newer chemotherapy regimens are competitive.
What are the main drivers of LEUKERAN's declining market share? The primary drivers are the availability of newer, more effective, and often better-tolerated targeted therapies and immunotherapies, coupled with evolving clinical practice guidelines that prioritize these advanced treatment options.
Is there any ongoing clinical development for LEUKERAN in new indications? There is no significant ongoing clinical development for LEUKERAN in new indications. Its clinical profile is well-established, and research efforts have shifted towards novel therapeutic classes.
What is the future outlook for the LEUKERAN market? The market outlook for chlorambucil is one of continued decline in developed countries due to competition from novel therapies. Its utility is expected to persist in specific niches, particularly in emerging markets or for certain patient populations where cost is a significant factor and advanced treatments are less accessible.

Citations

[1] National Cancer Institute. (n.d.). Chlorambucil (PDQ®)–Health Professional Version. Retrieved from https://www.cancer.gov/about-cancer/treatment/drugs/chlorambucil [2] European Medicines Agency. (n.d.). Summary of Product Characteristics - LEUKERAN. [3] U.S. Food & Drug Administration. (n.d.). Drug Search. [4] Market Research Reports (various oncology market analyses available through commercial providers like Grand View Research, Allied Market Research, etc. - specific report titles not cited as they are proprietary and dynamic). [5] ClinicalTrials.gov. (n.d.). Search for chlorambucil trials.

LEUKERAN Drug Patent Profile

Which patents cover Leukeran, and when can generic versions of Leukeran launch?

AI Deep Research

Questions you can ask:

Summary for LEUKERAN

US Patents and Regulatory Information for LEUKERAN

LEUKERAN (Chlorambucil) Investment Scenario and Fundamentals Analysis